multi-walled carbon nanotubes in vivo. <strong>Carbon</strong>45(7):1419−1424.Donaldson K, Borm PJ, Oberdörster G, Pinker<strong>to</strong>nKE, S<strong>to</strong>ne V, Tran CL [2008]. Concordance betweenin vitro <strong>and</strong> in vivo dosimetry in the proinflamma<strong>to</strong>ryeffects of low-<strong>to</strong>xicity, low-solubility particles:the key role of the proximal alveolar region. InhalToxicol 20(1):53–62.Driscoll KE, Carter JM, Howard BW, HassenbeinDG, Pepelko W, Baggs RB, Oberdörster G[1996]. Pulmonary inflamma<strong>to</strong>ry chemokine <strong>and</strong>mutagenic responses in rats after subchronic inhalationof carbon black. Toxicol Appl Pharmacol136(2):372–380.Duan N, Mage T [1997]. Combination of direct<strong>and</strong> indirect approaches for exposure assessment. JExpo Anal Environ Epidemiol 7(4):439–470.Ea<strong>to</strong>ugh DJ, Tang H, Cui W, Machir J [1995]. Determinationof the size distribution <strong>and</strong> chemicalcomposition of fine particulate semivolatile organicmaterial in urban environments using diffusiondenuder technology. Inhal Toxicol 7(5):691–710.Ea<strong>to</strong>ugh DJ, Ea<strong>to</strong>ugh DA, Lewis L, Lewis E [1996].Fine particulate chemical composition <strong>and</strong> lightextinction at Canyonl<strong>and</strong>s National Park using organicparticulate material concentrations obtainedwith multisystem, multichannel diffusion denudersampler. J Geophys Res 101(D14):19515–19531.Elder A, Gelein R, Finkelstein JN, Driscoll KE,Harkema J, Oberdörster G [2005]. Effects of subchronicallyinhaled carbon black in three species. I.Retention kinetics, lung inflammation, <strong>and</strong> his<strong>to</strong>pathology.Toxicol Sci 88(2):614–629.Elgrabli D, Abella-Gallart S, Robidel F, RogerieuxF, Boczkowski J, Lacroix G [2008a]. Induction ofapop<strong>to</strong>sis <strong>and</strong> absence of inflammation in rat lungafter intratracheal instillation of multiwalled carbonnanotubes. Toxicology 253(1–3):131–136 [Epubahead of print].Elgrabli D, Floriani M, Abella-Gallart S, MeuneirL, Gamez C, Delalain P, Rogerieux F, BoczkowskiJ, Lacroix G [2008b]. Biodistribution <strong>and</strong> clearanceof instilled carbon nanotubes in rat lung. Part FibreToxicol Dec 9;5:20 [http://dx.doi.org/10.1186/1743-8977-8-1510.1186/1743-8977-5-20].Ellinger-Ziegelbauer H, Pauluhn J [2009]. Pulmonary<strong>to</strong>xicity of multi-walled carbon nanotubes(Baytubes) relative <strong>to</strong> quartz following a single 6hinhalation exposure of rats <strong>and</strong> a 3 months postexposureperiod. Toxicology 266(1–3):16–29.Erdely A, Hulderman T, Salmen R, Lis<strong>to</strong>n A,Zeidler-Erdely PC, Schwegler-Berry D, CastranovaV, Koyama S, Kim YA, Endo M, Simeonova PP[2009]. Cross-talk between lung <strong>and</strong> systemic circulationduring carbon nanotube respira<strong>to</strong>ry exposure.Potential biomarkers. Nano Lett 1(9):36–43.Evans DE, Ku B-K, Birch ME, Dunn KH [2010].Aerosol moni<strong>to</strong>ring during carbon nanofiberproduction: mobile direct-reading sampling. AnnOccup Hyg 54(5):514–531.Fenoglio I, Greco G, Tomatis M, Muller J, Raymundo-Piñero, Béguin F, Fonseca A, Nagy JB, Lison D, FubiniB [2008]. Structural defects play a major rolein the acute lung <strong>to</strong>xicity of multiwall carbon nanotubes:physicochemical aspects. Chem Res Toxicol21(9):1690–1697.Ferris BG [1978]. Part II. Recommended respira<strong>to</strong>rydisease questionnaires for use with adults <strong>and</strong>children in epidemiologic research: epidemiologyst<strong>and</strong>ardization project. Am Rev Respir Dis 118(6,Part II):7–53.Fruin SA, Winer AM, Rodes CE [2004]. Black carbonconcentrations in California vehicles <strong>and</strong> estimationof in-vehicle diesel exhaust particulate matterexposures. Atmos Environ 38(25):4123–4133.Gao P, Jaques PA, Hsiao T, Shepherd A, Eimer BC,Yang M, Miller A, Gupta B, Shaffer R [2011]. Evaluationof nano- <strong>and</strong> submicron particle penetrationthrough ten nonwoven fabrics using a wind-drivenapproach. J Occup Environ Hyg 8(1):13–22.Gamo M (ed) [2011]. Risk assessment of manufacturednanomaterials: titanium dioxide (TiO 2). Final76 NIOSH CIB 65 • <strong>Carbon</strong> <strong>Nanotubes</strong> <strong>and</strong> <strong>Nanofibers</strong>
eport issued on July 22, 2011. NEDO project(P06041) “Research <strong>and</strong> development of nanoparticlecharacterisation methods.” Japan: New Energy<strong>and</strong> Industrial Technology Development Organization(NEDO).Golanski L, Guiot A, Rouillon F, Pocachard J, TardifF [2009]. Experimental evaluation of personalprotection devices against graphite nanoaerosols:fibrous filter media, masks, protective clothing, <strong>and</strong>gloves. Hum Exp Toxicol 28(6–7):353–359.Golanski L, Guiot A, Tardif F [2010]. Experimentalevaluation of individual protection devices againstdifferent types of nanoaerosols: graphite, TiO 2<strong>and</strong>Pt. J Nanopart Res 12(1):83–89.Gregorat<strong>to</strong> D, Bailey MR, Marsh JW [2010]. Modellingparticle retention in the alveolar-interstitial regionof the human lungs. J Radiol Prot 30(3):491–512.Gregorat<strong>to</strong> D, Bailey MR, Marsh JW [2011]. Particleclearance in the alveolar-interstitial region ofthe human lungs: model validation. Radiat ProtDosimetry 144(1–4):353–356.Grubek-Jaworska H, Nejman P, Czumińska K,Przybyłowski T, Huczko A, Lange H, BystrzejewskiM, Baranowski P, Chazan R [2006]. Preliminary resultson the pathogenic effects of intratracheal exposure<strong>to</strong> one-dimensional nanocarbons. <strong>Carbon</strong>44(6):1057–1063.Han JH, Lee EJ, Lee JH, So KP, Lee YH, Bae GN,Lee S-B, Ji JH, Cho MH, Yu IJ [2008a]. Moni<strong>to</strong>ringmultiwalled carbon nanotube exposure incarbon nanotube research facility. Inhal Toxicol20(8):741–749.Han SG, Andrews R, Gairola G, Bhalia D [2008b].Acute pulmonary effects of combined exposure <strong>to</strong>carbon nanotubes <strong>and</strong> ozone in mice. Inhal Toxicol20(4):391–398.Han SG, Andrews R, Gairola CG [2010]. Acutepulmonary response of mice <strong>to</strong> multi-wall carbonnanotubes. Inhal Toxicol 22(4):340–347.Harber P, Conlon C, McCunney RJ [2003]. <strong>Occupational</strong>medical surveillance. In: McCunney RJ,ed. A practical approach <strong>to</strong> occupational <strong>and</strong> environmentalmedicine. Philadelphia, PA: Lippincott,Williams, <strong>and</strong> Wilkins.Hinds WC [1999]. Respira<strong>to</strong>ry deposition, Chapter11. In: Hinds WC, ed. Aerosol Technology:Properties, Behavior, <strong>and</strong> Measurement of AirborneParticles, 2nd edition. New York: J. Wiley<strong>and</strong> Sons.Hou PX, Liu C, Cheng HM [2008]. Purification ofcarbon nanotubes. <strong>Carbon</strong> 15(46):2003–3025.Hubbs AF, Mercer RR, Coad JE, Battelli LA, WillardP, Sriram K, Wolfarth M, Castranova V, PorterD [2009]. Persistent pulmonary inflammation,airway mucous metaplasia <strong>and</strong> migration of multiwalledcarbon nanotubes from the lung after subchronicexposure. The Toxicologist 108:A2193.Hubbs AF, Mercer RR, Benkovic SA, Harkema J,Sriram K, Schwegler-Berry D, Goravanahally MP,Nurkiewicz TR, Castranova V, Sargent LM [2011].Nano<strong>to</strong>xicology—a pathologist’s perspective. ToxicolPathol 39(2):301–324.Huczko A, Lange H, Calko E, Grubek-Jaworska H,Droszcz P [2001]. Physiological testing of carbonnanotubes: are they asbes<strong>to</strong>s-like? Fullerene SciTechnol 9(2):251–254.Huczko A, Lange H, Bystrzejewski M, BaranowskiP, Grubek-Jaworska H, Nejman P, Przybyłowski T,Czumińska K, Glapiński J, Wal<strong>to</strong>n DRM, Kro<strong>to</strong>HW [2005]. Pulmonary <strong>to</strong>xicity of 1-D nanocarbonmaterials. Fullerenes, <strong>Nanotubes</strong>, <strong>and</strong> <strong>Carbon</strong>Nanostruct 13(2):141–145.IARC [2010]. IARC monographs on the evaluationof carcinogenic risks <strong>to</strong> humans: carbon black,titanium dioxide, <strong>and</strong> talc. Vol. 93. Lyon, France:World Health Organization, International Agencyfor Research on Cancer. Available at: http://monographs.iarc.fr/ENG/Monographs/vol93/index.php.ICRP [1994]. Human respira<strong>to</strong>ry tract model for radiologicalprotection. ICRP publication no. 66. In: SmithH, ed. Annals of the ICRP. Tarry<strong>to</strong>wn, New York: InternationalCommission on Radiological Protection.NIOSH CIB 65 • <strong>Carbon</strong> <strong>Nanotubes</strong> <strong>and</strong> <strong>Nanofibers</strong>77
- Page 1 and 2:
CURRENT INTELLIGENCE BULLETIN 65Occ
- Page 3 and 4:
Current Intelligence Bulletin 65Occ
- Page 5 and 6:
ForewordThe Occupational Safety and
- Page 7 and 8:
Executive SummaryOverviewCarbon nan
- Page 9 and 10:
2009; Pauluhn 2010a; Porter et al.
- Page 11 and 12:
neurogenic sig nals from sensory ir
- Page 13 and 14:
possible. Until the results from an
- Page 15 and 16:
••Follow exposure and hazard as
- Page 17 and 18:
Periodic Evaluations••Evaluatio
- Page 19 and 20:
ContentsForeword ..................
- Page 21 and 22:
A.3.2 Comparison of Short-term and
- Page 23 and 24:
ESPFeFMPSFPSSgGMGSDHCLHECHEPAhrISOI
- Page 25 and 26:
AcknowledgementsThis Current Intell
- Page 27 and 28:
1 IntroductionMany nanomaterial-bas
- Page 29:
2 Potential for ExposureThe novel a
- Page 32 and 33:
CNMs, with MWCNT agglomerates obser
- Page 34 and 35:
composite materials with local exha
- Page 36 and 37:
information on air contaminants. Sa
- Page 39 and 40:
3 Evidence for Potential Adverse He
- Page 41 and 42:
decreasing agglomerate size increas
- Page 43 and 44:
examined up to 60 days post-exposur
- Page 45 and 46:
3.3 SWCNT and MWCNTIntraperitoneal
- Page 47 and 48:
The same potency sequence was obser
- Page 49 and 50:
Table 3-3. Findings from published
- Page 51 and 52: Table 3-5. Findings from published
- Page 53 and 54: Table 3-6. Findings from published
- Page 55 and 56: Table 3-7 (Continued). Findings fro
- Page 57: Table 3-8. Findings from published
- Page 60 and 61: length, respectively) [Muller et al
- Page 63 and 64: 5 CNT Risk Assessment and Recommend
- Page 65 and 66: A-6). Risk estimates derived from o
- Page 67 and 68: Table 5-4. Factors, assumptions, an
- Page 69 and 70: and analytical methods. NIOSH is re
- Page 71 and 72: Table 5-5. Recommended occupational
- Page 73 and 74: deficits in animals or clinically s
- Page 75: (3) Rat lung dose estimationIn the
- Page 78 and 79: tasks where worker exposures exceed
- Page 80 and 81: As part of the evaluation of worker
- Page 82 and 83: Table 6-1. EC LODs and LOQs for 25-
- Page 84 and 85: 6.2 Engineering ControlsOne of the
- Page 86 and 87: Table 6-6 (Continued). Examples of
- Page 88 and 89: Table 6-7 (Continued). Engineering
- Page 90 and 91: exposure estimates for SWCNT on ind
- Page 92 and 93: Table 6-8. Respiratory protection f
- Page 94 and 95: ••Workers in areas or in jobs w
- Page 97 and 98: 7 Research NeedsAdditional data and
- Page 99 and 100: ReferencesACGIH [1984]. Particle si
- Page 101: Bolton RE, Vincent HJ, Jones AD, Ad
- Page 105 and 106: Kobayashi N, Naya M, Mizuno K, Yama
- Page 107 and 108: Methner M, Hodson L, Geraci C [2010
- Page 109 and 110: Human Services, Centers for Disease
- Page 111 and 112: Piegorsch WW, Bailer AF [2005]. Qua
- Page 113 and 114: AD, Baron PA [2003]. Exposure to ca
- Page 115: Varga C, Szendi K [2010]. Carbon na
- Page 119 and 120: ContentsA.1 Introduction ..........
- Page 121 and 122: A.1 IntroductionThe increasing prod
- Page 123 and 124: provide an informal check on the es
- Page 125 and 126: these same dose groups; this effect
- Page 127 and 128: Table A-1. Rodent study information
- Page 129 and 130: the deposited (no clearance) and th
- Page 131 and 132: The other BMDS models failed to con
- Page 133 and 134: Figure A-2. Benchmark dose model (m
- Page 135 and 136: Figure A-3 (continued). Benchmark d
- Page 137 and 138: Table A-3. Benchmark dose estimates
- Page 139 and 140: Table A-5. Benchmark dose estimates
- Page 141 and 142: histopathology grade 2 or higher lu
- Page 143 and 144: Table A-8. Working lifetime percent
- Page 145 and 146: developing early-stage adverse lung
- Page 147 and 148: Figure A-4. Dose-response relations
- Page 149 and 150: cell surface area). However, the wo
- Page 151 and 152: purified or unpurified (with differ
- Page 153 and 154:
Table A-9. Comparison of rat or hum
- Page 155 and 156:
A.6.1.3 Pulmonary Ventilation RateT
- Page 157 and 158:
used as the effect levels in evalua
- Page 159 and 160:
the DF estimate, although a larger
- Page 161 and 162:
or overloading, of particle clearan
- Page 163 and 164:
Table A-13. Human-equivalent retain
- Page 165 and 166:
A.7.1 Particle CharacteristicsBoth
- Page 167 and 168:
and density. The following MMAD and
- Page 169:
Table A-15. CNT lung dose normalize
- Page 172 and 173:
B.1 Key Terms Related toMedical Sur
- Page 175 and 176:
APPENDIX CNIOSH Method 5040
- Page 177 and 178:
filter. In the method evaluation, d
- Page 179 and 180:
Most of the studies on sampling art
- Page 181 and 182:
e analyzed to determine the onset o
- Page 184:
Delivering on the Nation’s promis